CLINICAL TRIAL: NORIG

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 本研究将确定胃轻瘫患者对去甲替林（一种症状调节剂/三环类抗抑郁药）治疗的临床反应。去甲替林被FDA批准用于治疗抑郁症。本研究将评价患者的症状和潜在的病理生理异常是否对去甲替林针对内脏高敏感性/中央处理的反应。虽然这种治疗剂在许多临床实践中用于胃轻瘫，但缺乏证据表明这种治疗对症状性胃轻瘫有效。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study will determine the clinical responses of patients with gastroparesis to treatment with nortriptyline, a symptom modulator/tricyclic antidepressant. Nortriptyline is FDA approved for treatment of depression. This study will evaluate whether patients= symptoms and underlying pathophysiologic abnormalities respond to nortriptyline directed towards visceral hypersensitivity/central processing. Although this therapeutic agent is employed in many clinical practices for gastroparesis, there is a lack of evidence that this treatment may be effective in symptomatic gastroparesis.